on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Advances Acquisition of relyon plasma GmbH
Viromed Medical AG has successfully completed the due diligence process for its planned acquisition of relyon plasma GmbH. A non-binding understanding on key acquisition terms has been reached with TDK Electronics AG, pending approval from TDK’s corporate bodies. Negotiations for the final purchase agreement are set for completion in the coming weeks. This marks a significant step, following a letter of intent signed on March 3, 2026.
relyon plasma GmbH specializes in modular systems and OEM components for industrial and medical applications, backed by a robust international patent portfolio. The company currently produces Viromed’s ViroCAP® and PulmoPlas® product lines. The acquisition promotes Viromed’s strategy of vertical integration, enhancing control over the value chain, reducing external reliance, and optimizing scalability.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news